BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 27418444)

  • 61. Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.
    Alizadeh F; Mahmoudinia M; Mirteimoori M; Pourali L; Niroumand S
    BMC Pregnancy Childbirth; 2022 Mar; 22(1):167. PubMed ID: 35232423
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
    Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
    Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
    [TBL] [Abstract][Full Text] [Related]  

  • 63. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO; Stamilio DM; Macones GA; Polsky D
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis.
    Lichter KE; Sheffield J; Graham EM; Eke AC
    J Matern Fetal Neonatal Med; 2020 Sep; 33(18):3177-3184. PubMed ID: 30626240
    [No Abstract]   [Full Text] [Related]  

  • 65. Does vaginal progesterone prevent recurrent preterm birth in women with a singleton gestation and a history of spontaneous preterm birth? Evidence from a systematic review and meta-analysis.
    Conde-Agudelo A; Romero R
    Am J Obstet Gynecol; 2022 Sep; 227(3):440-461.e2. PubMed ID: 35460628
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth.
    Elimian A; Smith K; Williams M; Knudtson E; Goodman JR; Escobedo MB
    Int J Gynaecol Obstet; 2016 Aug; 134(2):169-72. PubMed ID: 27168167
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Does progesterone treatment influence risk factors for recurrent preterm delivery?
    Meis PJ; Klebanoff M; Dombrowski MP; Sibai BM; Leindecker S; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S
    Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Utilization of hydroxyprogesterone caproate among pregnancies with live birth deliveries in the sentinel distributed database.
    Shinde M; Cosgrove A; Woods CM; Chang C; Nguyen CP; Moeny D; Ajao A; Kolonoski J; Tsai HT
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6291-6296. PubMed ID: 33926341
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
    Saghafi N; Khadem N; Mohajeri T; Shakeri MT
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
    Fernandez-Macias R; Martinez-Portilla RJ; Cerrillos L; Figueras F; Palacio M
    Int J Gynaecol Obstet; 2019 Nov; 147(2):156-164. PubMed ID: 31402445
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials.
    Sanchez-Ramos L; Kaunitz AM; Delke I
    Obstet Gynecol; 2005 Feb; 105(2):273-9. PubMed ID: 15684151
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study.
    Manuck TA; Watkins WS; Esplin MS; Biggio J; Bukowski R; Parry S; Zhan H; Huang H; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J; Yandell M; Varner MW; Jorde LB;
    BJOG; 2018 Feb; 125(3):343-350. PubMed ID: 28139890
    [TBL] [Abstract][Full Text] [Related]  

  • 73. 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: A randomized controlled trial.
    Pirjani R; Heidari R; Rahimi-Foroushani A; Bayesh S; Esmailzadeh A
    J Obstet Gynaecol Res; 2017 Jan; 43(1):57-64. PubMed ID: 27775195
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.
    Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Thom EA; Spong CY; Varner M; Malone F; Iams JD; Mercer BM; Thorp J; Sorokin Y; Carpenter M; Lo J; Ramin S; Harper M; Anderson G;
    N Engl J Med; 2007 Aug; 357(5):454-61. PubMed ID: 17671253
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
    How HY; Barton JR; Istwan NB; Rhea DJ; Stanziano GJ
    Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Progesterone therapy for prevention of recurrent spontaneous preterm birth in a minority patient population: a retrospective study.
    Mazza GR; Komatsu E; Ponzio M; Bai C; Cortessis VK; Sasso EB
    BMC Pregnancy Childbirth; 2024 Apr; 24(1):252. PubMed ID: 38589796
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
    Eke AC; Sheffield J; Graham EM
    Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time.
    Durnwald CP; Lynch CD; Walker H; Iams JD
    Am J Obstet Gynecol; 2009 Oct; 201(4):410.e1-5. PubMed ID: 19716117
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
    Oler E; Eke AC; Hesson A
    Int J Gynaecol Obstet; 2017 Jul; 138(1):12-16. PubMed ID: 28369874
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison the efficacy of vaginal progesterone
    Alavi A; Ranjbar A; Atighpoor F; Zare S
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):7438-7444. PubMed ID: 34470137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.